See more : PowerBand Solutions Inc. (PWWBF) Income Statement Analysis – Financial Results
Complete financial analysis of Praxis Precision Medicines, Inc. (PRAX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Praxis Precision Medicines, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Impact BioMedical Inc. (IBO) Income Statement Analysis – Financial Results
- Goldenmax International Technology Ltd. (002636.SZ) Income Statement Analysis – Financial Results
- Hindustan Oil Exploration Company Limited (HINDOILEXP.NS) Income Statement Analysis – Financial Results
- Headwater Exploration Inc. (CDDRF) Income Statement Analysis – Financial Results
- ASE Technology Holding Co., Ltd. (3711.TW) Income Statement Analysis – Financial Results
Praxis Precision Medicines, Inc. (PRAX)
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 2.45M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 1.17M | 1.59M | 746.00K | 679.00K | 1.00K |
| Gross Profit | 2.45M | -1.17M | -1.59M | -746.00K | -679.00K | -1.00K |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 86.77M | 155.04M | 120.26M | 44.98M | 29.56M | 18.82M |
| General & Administrative | 42.05M | 59.95M | 47.08M | 16.99M | 6.23M | 3.90M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 42.05M | 59.95M | 47.08M | 16.99M | 6.23M | 3.90M |
| Other Expenses | 0.00 | 957.00K | 271.00K | 140.00K | 0.00 | -3.65M |
| Operating Expenses | 128.82M | 214.99M | 167.33M | 61.97M | 35.79M | 22.72M |
| Cost & Expenses | 128.82M | 214.99M | 167.33M | 61.97M | 35.79M | 22.72M |
| Interest Income | 3.10M | 0.00 | 271.00K | 140.00K | 193.00K | 92.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 127.00K |
| Depreciation & Amortization | 432.00K | 1.17M | 1.59M | 746.00K | 679.00K | 1.00K |
| EBITDA | -125.94M | -212.86M | -165.47M | -61.08M | -34.92M | -26.27M |
| EBITDA Ratio | -5,146.75% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -126.37M | -214.99M | -167.33M | -61.97M | -35.79M | -22.72M |
| Operating Income Ratio | -5,164.41% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.10M | 957.00K | 271.00K | 140.00K | 193.00K | -3.68M |
| Income Before Tax | -123.28M | -214.03M | -167.06M | -61.83M | -35.60M | -26.40M |
| Income Before Tax Ratio | -5,037.88% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -957.00K | -182.00K | -8.00K | -84.00K | 133.00K |
| Net Income | -123.28M | -213.07M | -166.88M | -61.82M | -35.51M | -26.54M |
| Net Income Ratio | -5,037.88% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -18.69 | -69.33 | -58.96 | -103.61 | -348.24 | -306.73 |
| EPS Diluted | -18.69 | -69.33 | -58.96 | -103.61 | -348.24 | -306.73 |
| Weighted Avg Shares Out | 6.59M | 3.07M | 2.83M | 596.68K | 101.98K | 86.51K |
| Weighted Avg Shares Out (Dil) | 6.59M | 3.07M | 2.83M | 596.68K | 101.98K | 86.51K |
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
Praxis Precision Medicines to Host PRAX-628 Program Update
What Makes Praxis Precision Medicines, Inc. (PRAX) a Strong Momentum Stock: Buy Now?
Wall Street Analysts Think Praxis Precision Medicines, Inc. (PRAX) Could Surge 134.35%: Read This Before Placing a Bet
Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
Praxis Precision Medicines to Participate in TD Cowen's 44th Annual Health Care Conference
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
Source: https://incomestatements.info
Category: Stock Reports